Vulvovaginal candidiasis is considered recurrent when at least four specific episodes occur in one year or at least three episodes unrelated to antibiotic therapy occur within one year. Although greater than 50 percent of women more than 25 years of age develop vulvovaginal candidiasis at some time, fewer than 5 percent of these women experience recurrences. Clinical evaluation of recurrent episodes is essential. Patients who self-diagnose may miss other causes or concurrent infections. Known etiologies of recurrent vulvovaginal candidiasis include treatment-resistant Candida species other than , frequent antibiotic therapy, contraceptive use, compromise of the immune system, sexual activity and hyperglycemia. If microscopic examination of vaginal secretions in a potassium hydroxide preparation is negative but clinical suspicion is high, fungal cultures should be obtained. After the acute episode has been treated, subsequent prophylaxis (maintenance therapy) is important. • Vaginal candidiasis, acute or recurrent; when local therapy is not appropriate. • Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient. • Mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis. • Candidal balanitis when local therapy is not appropriate. • Dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated. • Tinea unguinium (onychomycosis) when other agents are not considered appropriate. • Relapse of cryptococcal meningitis in patients with high risk of recurrence.
Dose of 12 mg/kg once daily may be used, based on patient's response. This medication contains fluconazole. Do not take Diflucan if you are allergic to fluconazole. The antifungal drug Diflucan, taken just once a week, was found to reduce the frequency of infections by more than 90% in a six-month study involving nearly 400 women with a history of recurrent.